SQShaolong Qi

Shaolong Qi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shaolong Qi has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Guocan Yu

    Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology Department of Chemistry Tsinghua University Beijing P.R. China

    7 shared publications
  • Jianshi Du

    China-Japan Union Hospital of Jilin University, Jilin University, Jilin, China

    3 shared publications
  • Jie Zhou

    State Key Laboratory of Advanced Separation Membrane Materials Zhejiang Key Laboratory of Advanced Polymer Materials Modification and Application Technology College of Materials Science and Engineering Zhejiang University of Technology Hangzhou P. R. China

    3 shared publications
  • Xinyang Yu

    Department of Chemistry Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology Tsinghua University Beijing P. R. China

    3 shared publications
  • Yibin Cao

    State Key Laboratory of Advanced Separation Membrane Materials Zhejiang Key Laboratory of Advanced Polymer Materials Modification and Application Technology College of Materials Science and Engineering Zhejiang University of Technology Hangzhou P. R. China

    3 shared publications
  • Yundong Zhang

    3 shared publications

Latest Publications

  • Open Access

    A Supramolecular Thermal Switch for Precision Pyroptosis via Host−Guest Recognition and Electrostatic Interactions

    by Dan Wu, Jie Zhou, Yibin Cao, Kunmin Ping, Borui Zhao, Yanrong Yang, Chunyang Yu, Xinyang Yu, Shaolong Qi

    Cytomembrane‐puncturing gasdermin (GSDM)‐mediated pyroptosis activates antitumor immunity through the release of immunogenic cellular contents and proinflammatory cytokines. However, programmable and precise pyroptosis remains challenging due to the rigidity, inefficiency, and systemic toxicity of conventional inducers. Herein, a supramolecular thermal switch is engineered to enable precision pyroptosis induction. Triiodide ions (I 3 − ) are stabilized within β‐cyclodextrin ( β‐CD ) via host–guest recognition, enhancing payload efficiency and bioavailability, while calcium ions (Ca 2 + ), anchored on the periphery of β‐CD through electrostatic Ca 2 + /carboxylate interactions, nucleate CaCO 3 crystal growth. The resulting CaCO 3 matrix acts as a sustained Ca 2+ reservoir while preventing premature leakage of both Ca 2+ and I 3 − . In the acidic tumor microenvironment, CaCO 3 decomposes, enabling site‐specific release of I 3 − and Ca 2+ via a pH‐responsive disassembly mechanism. Under spatiotemporally controlled near‐infrared (NIR) laser irradiation, the boron dipyrromethene (BODIPY)‐based thermal switch is activated, converting biocompatible I 3 − into toxic iodine (I 2 ) and triggering a cascade of intracellular oxidative stress, mitochondrial damage and calcium buffer collapse. Synergizing with dysregulated Ca 2 + homeostasis, exogenous Ca 2 + burst induces Ca 2 + overload and cysteine‐aspartic acid protease‐3 (caspase‐3)/GSDME‐mediated pyroptosis, thereby connecting innate and adaptive immunity to inhibit tumor growth and metastasis. This supramolecular engineering strategy presents a promising approach for potentiating cancer immunotherapy.

  • Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD

    by Xinyang Yu, Shaolong Qi, Wanyue Cao, Meiqi Cheng, Wenjie Zhang, Yangfan Wang, Rujia Zheng, Gaowei Jin, Xiaomin Gao, Meixin Lu, et al.

    Metabolic dysfunction–associated fatty liver disease (MAFLD), a leading cause of hepatocellular carcinoma (HCC), poses a formidable therapeutic challenge because of the metabolic stress–induced aberrant immune microenvironment. However, no effective pharmacological therapies for the liver microenvironment remodeling in MAFLD are now available. Here, we developed a lipid nanoparticle (Def-LNP) that incorporates vitamin E–derived phosphatidylcholine (VEPC). Def-LNP effectively ameliorated the hepatic oxidative microenvironment to achieve sustained localized expression of target mRNA in hepatocytes in preclinical models, outperforming a commercially used LNP formulation. In vivo delivery efficiency, stability, and biosafety of Def-LNP were validated in various mammalian models, including mice, pigs, and nonhuman primates. Using clinical samples, we identified a pronounced correlation between T cell protein tyrosine phosphatase (TCPTP) and MAFLD pathogenesis. The administration of Def-LNP loaded with TCPTP-encoding mRNA (Def-LNP@mRNA TCPTP ) suppressed signal transducer and activator of transcription signaling in the hepatocytes of MAFLD mice, leading to hepatic metabolic reprogramming and immunological reconfiguration, a characteristic that is prominently lacking in conventional mRNA-based protein replacement therapy. In preclinical models, the administration of Def-LNP@mRNA TCPTP successfully eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved the therapeutic responsiveness of HCC to cancer vaccine and immune checkpoint blockade therapy. Def-LNP@mRNA TCPTP represents a potential therapeutic strategy for MAFLD and MAFLD-related HCC, potentially offering treatment paradigms for immunotherapy for HCC and metabolic liver diseases.


  • Open Access

    A broad−spectrum supramolecular host based on cucurbit[8]uril encapsulation for the reversal of neuromuscular blockade

    by Mengyao Li, Meiru Zhang, Rui Fei, Yundong Zhang, Danyu Xia, Shaolong Qi, Jianshi Du


  • Mineralization of macroaggregated albumin for accurate biodistribution evaluation of pre-radiotherapy

    by Xiaomin Gao, Mingru Zhang, Danlan Fang, Yuan Yu, Shaolong Qi, Xinyang Yu, Meiqi Cheng, Shoujun Zhu, Fei Kang, Kuikun Yang, et al.

    Conventional macroaggregated albumin (MAA) often fails to accurately simulate the biodistribution of 90Y microspheres in hepatic artery perfusion scintigraphy due to density mismatch. By mineralizing MAA, we developed lightly mineralized MAA (L-MAA) and highly mineralized MAA (H-MAA) with controlled densities, which enabled more accurate simulation of the biodistribution of resin and glass microspheres.

  • Open Access

    Inhaled non-viral delivery systems for RNA therapeutics

    by Cheng Huang, Hongjian Li, Xing Duan, Peidong Zhang, Shaolong Qi, Jianshi Du, Xiangrong Song, Aiping Tong, Guocan Yu


  • A sulfonated supramolecular host based on pillar[5]arene for succinylcholine-induced neuromuscular blockade reversal

    by Mengyao Li, Yujie Cheng, Rui Fei, Danyu Xia, Zibin Zhang, Shaolong Qi, Jianshi Du

    A per-sulfonated pillar[5]arene (SP[5]A) is designed as a reversal agent to reverse neuromuscular blockade induced by succinylcholine (Sch) via host–guest recognition. SP[5]A can rapidly and specifically recognize and encapsulate Sch in vivo for elimination with a binding affinity as high as 105 M−1. SP[5]A mitigates Sch-induced adverse reactions including hyperkalemia, arrhythmias, and rhabdomyolysis.


  • Open Access

    Coordinating interleukin-2 encoding circRNA with immunomodulatory lipid nanoparticles to potentiate cancer immunotherapy

    by Kai Yang, Bing Bai, Xiaomei Li, Wei Rou, Cheng Huang, Meixin Lu, Xueyan Zhang, Chunbo Dong, Shaolong Qi, Zhida Liu, et al.

    Interleukin-2 (IL-2) is a cytokine vital for CD8 + T cell activation and proliferation, holding great potential for cancer immunotherapy. Nevertheless, inherent shortcomings of short half-life, activation of regulatory T (T reg ) cells, and systemic toxicity limit its application. To tackle these, a circular RNA (cRNA)–based IL-2 therapy using immunomodulatory lipid nanoparticles [ursodeoxycholic acid lipid nanoparticles (ULNPs)] and sustained-release hydrogel was developed. Fusing fragment crystallizable (Fc) region into IL-2 and encoding this fusion protein IL-2-Fc (IL-2F) in cRNA (cRNA IL-2F ) greatly extend the half-life. ULNPs containing ursodeoxycholic acid, a transforming growth factor-β1 inhibitor, suppress the function of T reg cells. Consequently, the ULNPs-cRNA IL-2F formulation promotes CD8 + T cells and suppresses T reg cells, increasing the CD8 + /T reg ratio for effective immunotherapy. Furthermore, a locally administrated hydrogel loading with ULNPs-cRNA IL-2F sustains the release, enhancing efficacy and reducing toxicity. This innovative approach achieves remarkable tumor inhibition in both melanoma and orthotopic glioma models with or without surgery, offering a promising future for cancer immunotherapy.


  • Catalytic Hybrid Lipid Nanoparticles Potentiate Circle RNA-Based Cytokine Immunotherapy

    by Yongcan Li, Jinqun Gan, Jiaqi Lei, Shaolong Qi, Xinyang Yu, Weibing Zhang, Yunxuan Feng, Yundong Zhang, Meiqi Cheng, Lie Ma, et al.

    Cytokine therapeutics in cancer immunotherapy are greatly limited by their short half-time, serious toxicity, and frequent administration, which can possibly be addressed by ribonucleic acid (RNA) technology through the expression of targeting cytokines in situ. However, the intracellular translation of RNA remains restricted due to the generation of excessive reactive oxygen species (ROS) and overconsumption of adenosine triphosphate (ATP) within the transfected cells. Herein, hybrid lipid nanoparticles (Mn-LNPs) are developed by incorporating small-sized trimanganese tetraoxide nanoparticles within conventional lipid nanoparticles, showing the ability to generate oxygen, eliminate ROS, and boost intracellular ATP, thus greatly enhancing the translation efficiency. This hybrid platform is employed to encapsulate interleukin 12 (IL-12)-encoding circular RNA (Mn-LNPs@RNAIL-12) for tumor immunotherapy, exhibiting unparalleled advantages in the proliferation of cytotoxic T cells and stimulation of antitumor immunity. Moreover, the antitumor efficacy of Mn-LNPs@RNAIL-12 is further strengthened by synergizing with immune checkpoint blockade therapy to achieve durable and potent antitumor performances.


  • Open Access

    Hyaluronic acid modified indocyanine green nanoparticles: a novel targeted strategy for NIR-II fluorescence lymphatic imaging

    by Haiyan Zhang, Xinyu Wang, Yundong Zhang, Jinli Ma, Shaolong Qi, Jianshi Du, Chunxiang Jin

    The lymphatic system, alongside blood circulation, is crucial for maintaining bodily equilibrium and immune surveillance. Despite its importance, lymphatic imaging techniques lag behind those for blood circulation. Fluorescence imaging, particularly in the near-infrared-II (NIR-II) region, offers promising capabilities with centimeter-scale tissue penetration and micron-scale spatial resolution, sparking interest in visualizing the lymphatic system. Although indocyanine green (ICG) has been approved by the Food and Drug Administration (FDA) for use as a near-infrared-I (NIR-I) region fluorescent dye, its limitations include shallow penetration depth and low signal-to-noise ratio. Research suggests that ICG’s fluorescence emission tail in the second near-infrared window holds potential for high-quality NIR-II imaging. However, challenges like short circulation half-life and concentration-dependent aggregation hinder its wider application. Here we developed HA@ICG nanoparticles (NPs), a superior ICG-based NIR-II fluorescent probe with excellent biocompatibility, prolonging in vivo imaging, and enhancing photostability compared to ICG alone. Leveraging LYVE-1, a prominent lymphatic endothelial cell receptor that binds specifically to hyaluronic acid (HA), our nanoprobes exhibit exceptional performance in targeting lymphatic system imaging. Moreover, our findings demonstrate the capability of HA@ICG NPs for capillary imaging, offering a means to assess local microcirculatory blood supply. These compelling results underscore the promising potential of HA@ICG NPs for achieving high-resolution bioimaging of nanomedicines in the NIR-II window.